ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study (ORACLE)
Sponsor: Gyroscope Therapeutics Limited
Listed as NCT05481827, this PHASE2 trial focuses on Age Related Macular Degeneration (AMD) and remains ongoing. Sponsored by Gyroscope Therapeutics Limited, it has been updated 10 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Enrolling By Invitation PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Enrolling By Invitation PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Enrolling By Invitation PHASE2
-
Jan 2024 — Apr 2024 [monthly]
Enrolling By Invitation PHASE2
▶ Show 5 earlier versions
-
Dec 2023 — Jan 2024 [monthly]
Enrolling By Invitation PHASE2
Phase: None → PHASE2
-
Nov 2023 — Dec 2023 [monthly]
Enrolling By Invitation
-
Sep 2023 — Nov 2023 [monthly]
Enrolling By Invitation
-
Jan 2023 — Sep 2023 [monthly]
Enrolling By Invitation
-
Sep 2022 — Jan 2023 [monthly]
Enrolling By Invitation
First recorded
Jul 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gyroscope Therapeutics Limited
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .